KDOQI (Kidney Disease Outcomes Quality Initiative)

NKF KDOQI GUIDELINES

Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | History of KDOQI

 

KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease


Figures

Figure 1. The Evolution of National Kidney Foundation Guidelines for the Management of Dyslipidemias in Patients With Chronic Kidney Disease

Figure 2. Ages Covered by the Current Guidelines, and Those Covered by Previous Guidelines Developed for Use in the General Population

Figure 3. The Chain of Logic for Evidence Supporting the Treatment of Low-Density Lipoprotein Cholesterol in Patients With Chronic Kidney Disease

Figure 4. The Relative Coronary Heart Disease Risk Reduction in Subgroups of Patients From Major Lipid-Lowering Trials in the General Population

Figure 5. Causes of Death Among Period Prevalent Patients 1997-1999, Treated With Hemodialysis, Peritoneal Dialysis, or Kidney Transplantation

Figure 6. Example Demonstrating the Relative Contributions of VLDL and IDL Remnants to Non-HDL Cholesterol in Two Hypothetical Patients With Normal and High Triglycerides, Respectively

Figure 7. The Approach to Treatment of Dyslipidemias in Adults With Chronic Kidney Disease Used in These Guidelines

Figure 8. The Approach to Treatment of Dyslipidemias in Adolescents With Chronic Kidney Disease Used in These Guidelines

Figure 9. Expected Responses to Treatment of Low-Density Lipoprotein (Upper Panel), High-Density Lipoprotein (Middle Panel), and Triglycerides (Lower Panel), Based on Studies in the General Population


2003 National Kidney Foundation, Inc.